Home
News
Latest News
People Moves
Business Briefs
Newsletters
Features
Features
Reprints
Surveys
Editorial Calendar
Web Exclusives
Issue Archive
Events
MM&M Awards 2012
txt4pharma
MM&M Virtual Summit
Webcasts
Leadership Exchanges
Whitepapers
Directories
Creative Portfolio
Mobile Guide
Interactive Guide
Pharmaceutical Marketers Directory
MM&M Service Directory
Agency Gallery
Direct Marketing Showcase
Medical Education Review
Sales Force Listings
Jobs
About Us
Subscriber Services
Contact Us
Media Information
Editorial Advisory Board
Drug Info
New Drug Dossier
Drug Database
Subscribe
Order Now
Subscriber Services
Newsletters
RSS
|
Login
|
Register
Antidote Articles
Antidote: simvastatin
Marc Siegel, MD
June 15, 2011
The problem with a media-megaphoned report about a drug's potential side effect is that it too easily balloons into a fear-driven avoidance of a life-saving group of drugs.
Antidote: Vicodin
Marc Siegel, MD
May 13, 2011
A recent survey from IMS Health reveals that Vicodin is the most frequently prescribed painkiller in the US, with 131 million prescriptions written over the past year alone.
Antidote: generic drugs
Marc Siegel, MD
April 15, 2011
Use of generic drugs has grown dramatically in the US, to the point where currently almost 75% of the drugs we use are generic.
Antidote: potassium iodide
Marc Siegel, MD
March 15, 2011
Potassium iodide is a useful medication. It is also poorly understood, and has functioned as a "fear pill" in the current climate of radiation worries.
Antidote: influenza
Marc Siegel, MD
February 15, 2011
Influenza, like all viruses, has a simple structure. A package of genetic material (in this case RNA), is covered by a protein envelope.
Antidote: new cancer detection test
Marc Siegel, MD
January 14, 2011
Johnson & Johnson has received a lot of criticism lately because of the McNeil recalls of cold medicines, especially those for children. Factories must follow protocols which include sterility and proper oversights.
Antidote: aspirin
Marc Siegel, MD
December 15, 2010
Good old aspirin, therapeutic compound derived from willow bark, take a well-deserved bow. Well-publicized cases of aspirin induced bleeding are not the topic du jour.
Antidote: Coumadin
Marc Siegel, MD
November 15, 2010
I and every other clinician who treats patients with the common blood thinner warfarin (Coumadin) have a problem.
Antidote: cancer treatments
Marc Siegel, MD
October 15, 2010
There is an ongoing revolution occurring in the treatment of cancer. Unfortunately, it is easy for the public to miss the growing excitement for the new targeted therapies and vaccines because of the typical news media fascination with bad news rather than good.
Antidote: H1N1 flu vaccine
Marc Siegel, MD
September 15, 2010
There is a lot of confusion about this year's flu vaccine, in part because last year's novel H1N1 mild flu pandemic broke the usual mold on flu.
« Previous
Next »
Video Exclusive
Web Exclusives
Five industry experts advise specialty pharma company on digital strategy
April 20, 2012
Specialty pharma company POZEN assembled a crack team of experts to help shape its digital strategy. Not only did POZEN share with us the text from their contributions, but you can watch exclusive video clips of their valuable perspectives right here.
MM&M Awards 2011 HIghlights
The Best MM&M Awards Ever!
MAHF Ceremony 2012
Photos from the Medical Advertising Hall of Fame Awards ceremony
Most Popular
Most Emailed
Most Recent
Humira on solid ground, analysts say, despite vote on Pfizer hopeful
Goodbye Plavix, hello competition
Sales forces shrank in 2011, but not everywhere
Wolters Kluwer deals health analytics unit to private equity firm
RX-to-OTC proposal gets mixed reviews
Makers of pain pills, advocacy groups at center of Senate probe
Pharmas are from Mars, Payers are from Venus
Study: Young Latinas are key decision makers, prefer English
Coach vs. cancer in BMS-backed awareness effort
Indian conglomerate buys Manhattan Research parent for $635m
Harvard urges faculty to ditch journals
Study: Young Latinas are key decision makers, prefer English
Pharma Report 2012: Get Back in Shape
Massachusetts gift ban under attack (again)
Enbrel reps risk layoff, as Pfizer calls early end to US selling
Pfizer, Crestor tops for global promotional spend in 2011
Novo Nordisk plans US hiring spree as Q1 sales jump 10%
Med Ed Report: Show Me the Money
Wolters Kluwer deals health analytics unit to private equity firm
Humira on solid ground, analysts say, despite vote on Pfizer hopeful
No-see docs are know-nothings when it comes to new drug info, study suggests
E-prescriptions boost adherence data
How CDC's hep.-C testing advice benefits drugmakers now
PhRMA's Washington wish list
Study: Young Latinas are key decision makers, prefer English
Pharmas are from Mars, Payers are from Venus
Goodbye Plavix, hello competition
Indian conglomerate buys Manhattan Research parent for $635m
Sales forces shrank in 2011, but not everywhere
National plan seeks Alzheimer's treatment by 2025
Popular Topics
Acquisition
Adherence
App
Celebrity
Clinical Trial
Co-Marketing
Conflict Of Interest
Diabetes
Diagnostics
Digital
Direct To Consumer (DTC)
Disease Awareness
Downsize
Education & Awareness
FDA
Government
Guidance
Health Plans
HMOs
Hospitals
Insurers
Law
Marketing Research
Mobile
Sales Force